6 Jun 2013 07:00
Oxford BioMedica plc Change of Adviser and Broker
Oxford, UK - 6 June 2013: Oxford BioMedica ("the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that it has appointed Nomura Code Securities Limited as its sponsor, financial adviser and broker with immediate effect.
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications |
Tel: +44 (0)1865 783 000 |
Nomura Code Securities Juliet Thompson Jonathan Senior Christopher Golden
|
Tel: +44 (0)20 7776 1200 |
Media Enquiries: Mary-Jane Elliott/Sarah Macleod/Claire Dickinson M:Communications | Tel: +44 (0)20 7920 2360
|
Notes to editors
1. Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.
Oxford Biomedica (OXB)